What is Medeloop?
Medeloop operates at the intersection of artificial intelligence and clinical development. The company provides an end-to-end digital ecosystem that automates and optimizes the traditionally fragmented process of conducting clinical trials. By integrating disparate data streams and automating regulatory and operational workflows, Medeloop enables researchers to accelerate the path from discovery to clinical validation. Its market position is defined by its ability to reduce the time-to-market for life-saving therapies, addressing the high-cost, high-friction environment that currently characterizes global clinical research operations.
How much funding has Medeloop raised?
Medeloop has raised a total of $23.5M across 2 funding rounds:
Angel/Seed
$8M
Series A
$15.5M
Angel/Seed (2023): $8M with participation from Maven Ventures and General Catalyst
Series A (2024): $15.5M led by Maven Ventures, General Catalyst, Inovia, and Icon Ventures
Key Investors in Medeloop
Maven Ventures
Maven Ventures is a prominent seed-stage venture capital fund that focuses on backing software startups with the potential to build billion-dollar businesses and improve global outcomes.
General Catalyst
General Catalyst is a global venture capital firm that partners with founders to build enduring enterprises, providing deep operational expertise and strategic guidance across multiple growth stages.
Inovia
iNovia Capital is a full-stack venture firm that partners with visionary founders to build global technology companies, emphasizing a people-first investment philosophy.
What's next for Medeloop?
With the successful closure of this major enterprise-level funding, Medeloop is poised to scale its operational footprint and enhance its AI capabilities. The strategic capital will likely be deployed toward expanding its engineering team, deepening its data integration partnerships, and accelerating the adoption of its platform among mid-to-large scale pharmaceutical entities. As the industry shifts toward decentralized and data-heavy trial models, Medeloop is well-positioned to capture significant market share by providing the technological backbone necessary for next-generation medical innovation.
See full Medeloop company page
